Clinical trials
Completed Observational Virus Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
92 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 26 |
| 2021 | 7 |
| 2022 | 13 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 92 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ModernaTX, Inc. | 7 |
| National Cancer Institute (NCI) | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Hospices Civils de Lyon | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| University Hospital, Lille | 3 |
| Centre Hospitalier Universitaire de Nice | 2 |
| Merck Sharp & Dohme LLC | 2 |
| National Institutes of Health Clinical Center (CC) | 2 |
| Rigshospitalet, Denmark | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Virus Diseases | 92 |
| COVID-19 | 25 |
| Coronavirus Infections | 16 |
| Respiratory Tract Infections | 11 |
| Bacterial Infections | 10 |
| Infections | 9 |
| Influenza, Human | 5 |
| DNA Virus Infections | 4 |
| Hepatitis | 4 |
| Asthma | 3 |
Trials
Showing 1 to 25 of 92. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.